Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Interactive Features

Quiz
Are PD-L1 Scores Predictive of TP53 Mutation Rates?
02/13/2023
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential...
02/13/2023
Oncology
Quiz
Are PD-L1 Scores Predictive of TP53 Mutation Rates?
02/13/2023
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential...
02/13/2023
Oncology

Advertisement

Quiz
Quiz: Targeted Therapies for EGFR-Mutant Lung Cancer
12/02/2022
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an...
12/02/2022
Oncology
Quiz
Quiz: Targeted Therapies for EGFR-Mutant Lung Cancer
12/02/2022
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an...
12/02/2022
Oncology
Test Your Knowledge
Quiz: Combination Therapies as Treatment Options for EGFR-Mutated Lung Cancer
11/30/2022
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are...
11/30/2022
Oncology

Advertisement

Test Your Knowledge
Quiz: Combination Therapies as Treatment Options for EGFR-Mutated Lung Cancer
11/30/2022
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are...
11/30/2022
Oncology
Quiz
Quiz: Which somatic missense non-synonymous single nucleotide polymorphisms were recently determined to be putative novel rare genetic markers for NSCLC?
10/12/2022
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool...
10/12/2022
Oncology
Quiz
Quiz: Which somatic missense non-synonymous single nucleotide polymorphisms were recently determined to be putative novel rare genetic markers for NSCLC?
10/12/2022
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool...
10/12/2022
Oncology

Advertisement

Quiz
Quiz: Bevacizumab Plus Erlotinib for EGFR-Mutated Advanced NSCLC
09/14/2022
What improvement in PFS rates did the phase 3 BEVERLY trial find among patients with EGFR-mutated NSCLC receiving treatment of bevacizumab plus erlotinib vs those treated with erlotinib alone? The phase 3 BEVERLY trial found evidence of...
What improvement in PFS rates did the phase 3 BEVERLY trial find among patients with EGFR-mutated NSCLC receiving treatment of bevacizumab plus erlotinib vs those treated with erlotinib alone? The phase 3 BEVERLY trial found evidence of...
What improvement in PFS rates...
09/14/2022
Oncology
Quiz
Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC
07/25/2022
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS...
07/25/2022
Oncology

Advertisement

Advertisement

Advertisement

Recent News

FDA Alerts
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/18/2024
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL...
10/18/2024
Oncology
FDA Approval
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
News
Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
FDA Approval
FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
10/10/2024
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis
10/10/2024
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated,...
10/10/2024
Oncology
News
Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma
10/10/2024
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and...
10/10/2024
Oncology
News
Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma
10/10/2024
While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...
While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...
While allogeneic stem cell...
10/10/2024
Oncology
News
Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer
10/09/2024
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the...
10/09/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use